GlassScriptPhysician profile
Jennifer Williams
NPI 1396007100
$1,205.14
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $799 · 2020: $170 · 2021: $237.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $342.56 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $179.07 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $129.20 | 2019-2020 | |
| Glaxosmithkline, LLC. | $109.65 | 2019 | |
| Philips North America LLC | $81.64 | 2019 | |
| United Therapeutics Corporation | $62.04 | 2020-2021 | |
| Abbvie INC. | $57.03 | 2021 | |
| Novartis Pharmaceuticals Corporation | $50.82 | 2019 | |
| Shire North American Group INC | $38.64 | 2019 | |
| Insmed, INC. | $33.06 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $28.74 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.36 | 2020 | |
| Sunovion Pharmaceuticals INC. | $21.13 | 2019 | |
| Merck Sharp & Dohme LLC | $19.48 | 2019 | |
| Mylan Specialty L.P. | $16.04 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $12.68 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.